Quilizumab

Drug Profile

Quilizumab

Alternative Names: Anti M1 prime monoclonal antibody; MEMP-1972A; RG-7449

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genentech
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Immunoglobulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic asthma; Allergic rhinitis; Urticaria

Most Recent Events

  • 28 Jan 2015 Discontinued - Phase-I for Allergic rhinitis in Canada (Parenteral)
  • 28 Jan 2015 Discontinued - Phase-II for Allergic asthma (Prevention) in Canada (IV)
  • 28 Jan 2015 Discontinued - Phase-II for Allergic asthma (Prevention) in Sweden (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top